Search clinical trials for: CDK 4/6 inhibitor

Total 81096 results

Assiut University

Completed

Outcomes of a New Trans-epithelial Photorefractive Keratectomy (Streamlight PRK) Compared to Conventional PRK Procedures

Myopia ≤ -6 Diopters or Myopic Astigmatism ≤ -4 Diopters

Egypt
Borstkanker Onderzoek Groep

Active, not recruiting

Endocrine Therapy Plus CDK4/6 in First or Second Line for Hormone (SONIA) Receptor Positive Advanced Breast Cancer

Breast Neoplasm Female

Netherlands
German Breast Group
Pfizer; AGO Study Group; Breast International Group; NSABP Foundation Inc

Completed

A Study of Palbociclib in Addition to Standard Endocrine Treatment in Hormone Receptor Positive Her2 Normal Patients With Residual Disease After Neoadjuvant Chemotherapy and Surgery (PENELOPE-B)

Breast Cancer | Hormonreceptor Positive | Her2-normal | Postneoadjuvant Treatment With CDK 4/6 Inhibitor | CPS-EG Score

United States, Australia, Austria, Canada, France, Germany, Ireland, Japan, Korea, Republic of, Spain, United Kingdom
Genelux Corporation

Temporarily not available

Expanded Access to Provide GL-ONC1 for the Treatment of Advanced Cancers With No Standard of Care

Advanced Stage Cancer (Solid Tumor Disease for 4 Patients) | Acute Myeloid Leukemia (6 Patients)

United States
Eli Lilly and Company

Completed

A Neoadjuvant Study of Abemaciclib (LY2835219) in Postmenopausal Women With Hormone Receptor Positive, HER2 Negative Breast Cancer (neoMONARCH)

Breast Cancer | Early-Stage Breast Carcinoma | Hormone Receptor Positive Tumor

United States, Canada, Korea, Republic of, Italy, Austria, Belgium, Germany, Netherlands, Spain, Taiwan
UCB Pharma

Terminated

A 12 Week Study to Assess Changes in Joint Inflammation Using Ultrasonography in Patients With Rheumatoid Arthritis (RA) (SWIFT)

Rheumatoid Arthritis

United States
AstraZeneca
PRA Health Sciences

Completed

Pharmacokinetics, Safety & Tolerability of ZD4054 (Zibotentan) in Subjects With Normal, Mild, Moderate and Severe Hepatic Impairment

Hepatic Impairment

Czech Republic
G1 Therapeutics, Inc.

Completed

Trilaciclib (G1T28), a CDK 4/6 Inhibitor, in Combination With Etoposide and Carboplatin in Extensive Stage Small Cell Lung Cancer (SCLC)

Small Cell Lung Cancer

Spain, United States, Georgia, France, Moldova, Republic of, Hungary, Poland
Namik Kemal University

Not yet recruiting

Evaluation of Geriatric Questionnaires to Predict Toxicities of CDK 4/6 Inhibitors in Older Breast Cancer Patients?

Can the Geriatric Questionnaires Predict Adverse Effects in Geriatric Breast Cancer Patients Treated With Cyclin-dependent Kinase 4 and 6 Inhibitors

Turkey
Maisonneuve-Rosemont Hospital

Completed

Inspiratory Support Improves Preoxygenation in Healthy Subjects

Healthy

Canada
UCB Pharma

Completed

Safety Study of CDP7657 in Healthy Volunteers and Patients With Systemic Lupus Erythematosus (SLE)

Immune System Diseases | Autoimmune Diseases | Lupus Erythematosus, Systemic | Skin and Connective Tissue Diseases | Connective Tissue Disease

Belgium, Bulgaria, Germany
G1 Therapeutics, Inc.

Completed

First-in-Human Safety, PK, and Food Effect Study of Single Ascending Doses of G1T38 in Healthy Volunteers

Healthy Volunteers

Netherlands
RWTH Aachen University

Unknown

Evaluation of the High-resolution, Contrast Enhanced Low-dose Breast-CT

BI-RADS 4 | BI-RADS 5 | BI-RADS 6 | High Risk of Breast Cancer Which Indicates a Mamma-MRI
Zeno Alpha Inc.

Completed

A Study of ZN-c5 and Abemaciclib in Participants With Breast Cancer

Breast Cancer

United States, Poland
Tokyo University
Human Genome Center, Institute of Medical Science, University of Tokyo

Completed

Histocompatibility Leukocyte Antigen (HLA)-A*2402 Restricted Peptide Vaccine Therapy in Patients With Gastric Cancer

Gastric Cancer

Japan
Tokyo University
Human Genome Center, Institute of Medical Science, University of Tokyo

Completed

Histocompatibility Leukocyte Antigen (HLA)-A*0201 Restricted Peptide Vaccine Therapy in Patients With Esophageal Cancer

Esophageal Cancer

Japan
Tokyo University
Human Genome Center, Institute of Medical Science, University of Tokyo

Completed

Histocompatibility Leukocyte Antigen (HLA)-A*2402 Restricted Peptide Vaccine Therapy in Patients With Esophageal Cancer

Esophageal Cancer

Japan
Tokyo University
Human Genome Center, Institute of Medical Science, University of Tokyo

Completed

Histocompatibility Leukocyte Antigen (HLA)-A*0201 Restricted Peptide Vaccine Therapy in Patients With Gastric Cancer

Gastric Cancer

Japan
West German Study Group
AGO Germany

Completed

4 x Epirubicin, Cyclophosphamide, Followed by 4 x Docetaxel Versus 6 x CMF / 6 x CEF

Breast Cancer

Germany
Merck Sharp & Dohme LLC

Completed

A Study to Evaluate the Safety, Immune Response, and Efficacy of Gardasil (V501, qHPV) in Mid-Adult Women (V501-019)

Prevention | Papillomavirus Infection | Healthy Adult Female Participants | Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18
G1 Therapeutics, Inc.

Completed

Safety, Pharmacokinetic and Pharmacodynamic Study of the CDK 4/6 Inhibitor G1T28-1

Healthy Volunteers

Netherlands
UCB Japan Co. Ltd.

Completed

A Trial to Evaluate the Long Term Safety and Tolerability of Lacosamide Taken as Monotherapy in Adults With Partial-onset Seizures

Epilepsy | Partial-onset Seizures

Japan
Grünenthal GmbH

Completed

Evaluation of Effectiveness and Tolerability of Tapentadol Hydrochloride in Subjects With Severe Chronic Low Back Pain Taking Either WHO Step I or Step II Analgesics or no Regular Analgesics

Low Back Pain | Chronic Pain

Austria, Germany, United Kingdom, Croatia, France, Italy, Poland, Spain, Switzerland
Eisai Limited
Merck Sharp & Dohme LLC

Completed

A Multicenter, Open-Label, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib (E7080) Versus Sorafenib in First-line Treatment of Participants With Unresectable Hepatocellular Carcinoma

Hepatocellular Carcinoma (HCC)

Italy, Korea, Republic of, Poland, United States, Australia, Belgium, Canada, China, France, Germany, Hong Kong, Israel, Japan, Malaysia, Philippines, Russian Federation, Singapore, Spain, Taiwan, Thailand, United Kingdom
Iconic Therapeutics, Inc.

Terminated

Open-Label Study of Intravitreal ICON-1 in Patients With Choroidal Neovascularization Secondary to Age-related Macular Degeneration (AMD) (DECO)

Choroidal Neovascularization | Wet Macular Degeneration

United States
NiKang Therapeutics, Inc.

Recruiting

A Study With NKT3447 for Adults With Advanced/Metastatic Solid Tumors

Small Cell Lung Carcinoma | Gastric Cancer | Ovarian Neoplasms | Ovarian Cancer | Solid Tumor | Endometrial Neoplasms | Triple Negative Breast Cancer | Triple Negative Breast Neoplasms | Advanced Solid Tumor | Endometrial Cancer | Small-cell Lung Cancer | Platinum-resistant Ovarian Cancer | Ovarian Carcinoma | Solid... and other conditions

United States
Parc de Salut Mar

Recruiting

Four or Six Weeks of Immobilization in the Conservative Treatment of Distal Radius Fractures in Elderly Population?

Distal Radius Fracture

Spain
Cork University Hospital

Not yet recruiting

Distal Radial Fractures in Adult Patients: 4 Weeks Versus 6 Weeks of Cast Immobilisation Following Closed Reduction.

Distal Radius Fracture

Ireland
University of Hohenheim
Universität Tübingen

Completed

Increasing the Oral Bioavailability of 6-prenylnaringenin by Micellar Solubilization

Safety of Native vs. Micellar 6-PN After Oral Intake | Pharmacokinetics of Native vs. Micellar 6-PN After Oral Intake | PBMC Activity After Native vs. Micellar 6-PN Oral Intake

Germany
Revance Therapeutics, Inc.

Completed

Efficacy and Safety of DaxibotulinumtoxinA (DAXI) for Injection for Treatment of Upper Facial Lines

Upper Facial Lines (Glabellar Lines, Forehead Lines, & Lateral Canthal Lines)

United States, Canada
University of Milano Bicocca

Recruiting

Retrospective Study of 2nd-line Therapies After CDK4/6i + Hormonal Therapy in HR+/HER2- Advanced Breast Cancer (HERMIONE-13)

Advanced Breast Cancer | Hormone Receptor Positive Breast Carcinoma | HER2-negative Breast Cancer

Italy
Klinikum der Universität Köln

Unknown

Comparison of TOT 8/4 Versus TOT 6/3 (URGE-III)

Urinary Incontinence

Germany
Universitat Internacional de Catalunya

Recruiting

Analysis Acceleration/Deceleration Distance Gait Speed Tests in Stroke Survivors (Walk-test)

Stroke | Chronic Stroke

Spain
Fudan University

Recruiting

Initial CDK 4/6 Inhibitor Plus Endocrine Therapy Versus Initial Chemotherapy in HR Positive, HER2 Negative Unresectable or Metastatic Breast Cancer

Breast Cancer

China
CanSino Biologics Inc.

Active, not recruiting

A Clinical Trial of ACYW135 Group Meningococcal Polysaccharide Conjugate Vaccine (CRM197 Vector) in a 4 to 6 Year-old Population

Epidemic Meningitis

China
Thesan Pharmaceuticals, Inc.

Withdrawn

TSN2898-201 Safety and Efficacy of TSN2898 in the Treatment of Acne Vulgaris

Acne Vulgaris

United States, Dominican Republic, Honduras
Hamilton Health Sciences Corporation

Terminated

Level of Continuous Positive Airway Pressure (CPAP) in Preterm Infants After Extubation (L-CPAP Study) (L-CPAP)

Respiratory Insufficiency of Prematurity
Kari Wisinski
Novartis; University of Wisconsin, Madison; Big Ten Cancer Research Consortium

Recruiting

Ribociclib and Bicalutamide in AR+ TNBC

Triple Negative Breast Cancer

United States
Chinese PLA General Hospital
Sinotau Pharmaceutical Group

Completed

First in Human Study of 68Ga/64Cu-FAPI-XT117 PET/CT in Patients With Malignant Solid Tumors

Malignant Solid Tumors

China
Masimo Corporation

Completed

Spot-Check Noninvasive Hemoglobin (SpHb) Clinical Validation

Healthy | Anemia | Pediatric ALL

United States
Regeneron Pharmaceuticals
Sanofi

Completed

A Study to Assess the Efficacy and Safety of Dupilumab in Participants With Severe Atopic Dermatitis (AD) That Are Not Controlled With Oral Cyclosporine A (CSA) or for Those Who Cannot Take Oral CSA Because it is Not Medically Advisable

Atopic Dermatitis

Germany, Poland, Belgium, Netherlands, Russian Federation, Ireland, United Kingdom, Slovakia, Austria, Spain
University of Chicago
National Institutes of Health (NIH); University of Houston

Not yet recruiting

Quantitative Assessment of Autologous Fat Transfer

Autologous Fat Grafting
Novartis

Terminated

Safety and Efficacy of Tegaserod in Opioid-induced Constipation in Patients With Non-cancer Pain.

Opioid-induced Constipation

United States, China, Egypt, Singapore, Taiwan, Venezuela
Sanol GmbH

Completed

A Double-blind, Double-dummy, Parallel, Active-controlled, Randomized Trial to Evaluate Efficacy & Safety in Anemia Subjects

Iron Deficiency Anemia

China
Kantonsspital Baden
University Hospital Inselspital, Berne

Unknown

Sienna+® Injection Time Study 4 Arms (Sentimag02)

Breast Neoplasms

Switzerland
Kowa Research Institute, Inc.

Completed

Pharmacokinetic Drug-Drug Interaction Study Between K-877 and CSG452 in Healthy Adult Volunteers

Healthy

United States
Sanofi
Kowa Company, Ltd.

Completed

TOFO Insulin Combination Trial

Type 2 Diabetes Mellitus

Japan
G1 Therapeutics, Inc.

Terminated

Trilaciclib (G1T28), a CDK 4/6 Inhibitor, in Combination With Gemcitabine and Carboplatin in Metastatic Triple Negative Breast Cancer (mTNBC)

Breast Cancer | Breast Neoplasm | Triple-Negative Breast Cancer | Triple-Negative Breast Neoplasms

United States, Bulgaria, Croatia, Slovenia, Serbia, Belgium, North Macedonia, Slovakia
Tianjin Medical University Cancer Institute and...

Not yet recruiting

Advanced Breast Cancer Study of CDK4/6 Inhibitor Combined With Endocrine Therapy Endocrine Therapy in HR+/HER2- Advanced Breast Cancer

Advanced HR+ HER2 Negative Breast Carcinoma
Grünenthal GmbH

Terminated

Evaluation of Effectiveness and Tolerability of Tapentadol Hydrochloride in Subjects With Severe Pain Due to Osteoarthritis Taking WHO Step III Analgesics But Showing a Lack of Tolerability.

Osteoarthritis | Chronic Pain

Germany, United Kingdom, Spain, Australia, Denmark, Poland

Search clinical trials for: CDK 4/6 inhibitor

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Portugal

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations